Skip to main content

Advertisement

Table 4 Cost–utility when age limit is raised to 60 and 70 years (representing an annual cohort from England)

From: A model-based assessment of the cost–utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients

Scenario Base case (CRC under 50 years) CRC under 60 years CRC under 70 years
Incremental costs of Strategy 5 vs Strategy 1(1) [£ Thousands]
Diagnosis 586.0 1590.5 4132.2
CRC prevention 817.1 1630.3 2990.5
CRC treatment −725.2 −1450.7 −2604.6
EC prevention 374.5 772.5 1430.4
EC treatment −68.0 −139.2 −247.9
Total 984.5 2403.4 5700.5
Incremental QALYs Strategy 5 vs Strategy 1(1)
Short-term −4.6 −9.5 −18.1
Long-term 183.9 322.4 574.4
Total 179.3 312.9 556.3
Cost–utility of Strategy 5 vs Strategy 1(1)
ICER [cost per QALY gained] £5491 £7681 £10247
INHB at WTP £20,000/QALY [QALYs] 130.1 192.8 271.3
  1. Abbreviations: EC endometrial cancer, WTP willingness-to-pay.